A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein

Anzhong Li, Jingyou Yu, Mijia Lu, Yuanmei Ma, Zayed Attia, Chao Shan, Miaoge Xue, Xueya Liang, Kelsey Craig, Nirajkumar Makadiya, Jennifer J. He, Ryan Jennings, Pei-Yong Shi, Mark E. Peeples, Shan-Lu Liu, Prosper N. Boyaka and Jianrong Li ()
Additional contact information
Anzhong Li: The Ohio State University
Jingyou Yu: The Ohio State University
Mijia Lu: The Ohio State University
Yuanmei Ma: The Ohio State University
Zayed Attia: The Ohio State University
Chao Shan: University of Texas Medical Branch
Miaoge Xue: The Ohio State University
Xueya Liang: The Ohio State University
Kelsey Craig: The Ohio State University
Nirajkumar Makadiya: The Ohio State University
Jennifer J. He: The Ohio State University
Ryan Jennings: The Ohio State University
Pei-Yong Shi: University of Texas Medical Branch
Mark E. Peeples: The Research Institute at Nationwide Children’s Hospital
Shan-Lu Liu: The Ohio State University
Prosper N. Boyaka: The Ohio State University
Jianrong Li: The Ohio State University

Nature Communications, 2018, vol. 9, issue 1, 1-17

Abstract: Abstract Current efforts to develop Zika virus (ZIKV) subunit vaccines have been focused on pre-membrane (prM) and envelope (E) proteins, but the role of NS1 in ZIKV-specific immune response and protection is poorly understood. Here, we develop an attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing ZIKV prM-E-NS1 as a polyprotein. This vectored vaccine candidate is attenuated in mice, where a single immunization induces ZIKV-specific antibody and T cell immune responses that provide protection against ZIKV challenge. Co-expression of prM, E, and NS1 induces significantly higher levels of Th2 and Th17 cytokine responses than prM-E. In addition, NS1 alone is capable of conferring partial protection against ZIKV infection in mice even though it does not induce neutralizing antibodies. These results demonstrate that attenuated rVSV co-expressing prM, E, and NS1 is a promising vaccine candidate for protection against ZIKV infection and highlights an important role for NS1 in ZIKV-specific cellular immune responses.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-05276-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05276-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-05276-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().